

Direct Access to Various 1-Substituted-imidazo[1,5-*a*]pyridine-3(2*H*)-thione Derivatives

Ikyon Kim,* Ge Hyeoung Lee, and Zae Sung No

Medicinal Science Division, Korea Research Institute of Chemical Technology, Daejeon 305-600, Korea

*E-mail: ikyon@kRICT.re.kr

Received January 28, 2007

Key Words : 1-Substituted-imidazo[1,5-*a*]pyridine-3(2*H*)-thione. Nucleophilic addition. Organometallic reagents. *N*-Silylaldimines. 1-Substituted (pyridin-2-yl)methylamines

In connection with our medicinal chemistry research program, we were interested in preparing a series of 1-substituted-imidazo[1,5-*a*]pyridine-3(2*H*)-thione derivatives (Figure 1).

Although synthesis of 1-phenyl-imidazo[1,5-*a*]pyridine-3(2*H*)-thione (**1**) has been reported previously by Glover and coworkers,¹ its analogues, compounds possessing diverse R₁ and R₂ groups, have not been known to date.² Therefore, we decided to investigate the synthesis of its various derivatives and evaluate them as a novel scaffold for new drug development. However, precedented synthesis of **1** requires many steps (Scheme 1).¹ Thus, phenyl-2-pyridyl ketone (**2**) was first converted to the corresponding oxime, which upon reduction with Zn in acetic acid, provided the amine **3**.³ The

reaction of amine **3** with phenyl isothiocyanate led to the thiourea **4** which was heated to reflux in xylene to afford **1**. In addition, phenyl-2-pyridyl ketone (**2**) itself has to be synthesized.⁴

In order to make a wide variety of 1-substituted-imidazo[1,5-*a*]pyridine-3(2*H*)-thione derivatives efficiently, more direct route was sought. In this communication, we wish to report an expedient synthesis of 1-substituted-imidazo[1,5-*a*]pyridine-3(2*H*)-thione analogues.

As retrosynthetically shown in Scheme 2, it was conceived that cyclic thioureas **5** should be derived from amines **6**, which in turn could be obtained from the commercially available 2-pyridinecarboxaldehyde (**8**) via the addition of various organometallic species (RM) to the aldimines **7** (route A).⁵ Alternatively, amines **6** could be constructed from the addition of **9** to aldimines **10** which should be available from aldehydes **11** (route B).

In both routes, *in situ* formation of aldimines would be desirable in order to increase efficiency. Among the methods to make aldimines *in situ* from aldehydes, Hart's procedure⁶ was elected since the adduct, *N*-silylated amines, can be easily hydrolyzed to generate primary amines **6** directly during the aqueous work-up. Surprisingly, this protocol has not







Figure 1



Scheme 1



Scheme 2. Retrosynthetic analysis.



Scheme 3

been exploited frequently with nitrogen-containing hetero-aromatic aldehydes such as 2-pyridinecarboxaldehyde.⁷ Since it is difficult to make *N*-TMS aldimines **10** from aldehydes **11** in some cases,⁸ we first opted to use the route


A.

Thus, a solution of 2-pyridinecarboxaldehyde (**8**) was treated with lithium bis(trimethylsilyl)amide (LHMDS) at 0 °C to afford *N*-trimethylsilylaldimine, which was then

Table 1.

Entry	Aldehydes	RM	Temp ^a	6 ^b	5 ^b	Work-up ^c	Entry	Aldehydes	RM	Temp ^a	6 ^b	5 ^b	Work-up ^c
1			0	6a (89)	5a (82)	A	16	8	MeMgCl	0	6p (95)	5p (81)	C
2	8		0	6b (93)	5b (85)	A	17	8	EtMgBr	-78	6q (98)	5q (79)	C
3	8		0	6c (88)	5c (90)	A	18	8	<i>i</i> -PrMgCl	-78	6r (93)	5r (80)	C
4	8		-78	6d (79)	5d (92)	B	19	8		0	6s (96)	5s (75)	C
5	8		-78	6e (75)	5e (82)	B	20	8	<i>n</i> -BuLi	0	6t (94)	5t (83)	C
6	8		0	6f (80)	5f (81)	B	21	8		0	6u (92)	5u (80)	A
7	8		-78	6g (83)	5g (84)	B	22	8		-78	6v (79)	5v (76)	B
8	8		-78	6h (78)	5h (91)	B	23	8		-78	6w (84)	5w (72)	B
9	8		0	6i (81)	5i (85)	B	24	8		-78	6x (75)	5x (81)	B
10	8		-78	6j (78)	5j (82)	B	25	8		0	6y (90)	5y (83)	B
11	8		-78	6k (89)	5k (81)	A	26	8		0	6z (80)	5z (77)	B
12	8		-78	6l (88)	5l (86)	B	27	8		-78	6aa (78)	5aa (75)	B
13	8		-78	6m (89)	5m (93)	B	28	8		-78	6bb (70)	5bb (76)	B
14	8		-78	6n (82)	5n (91)	B	29	8		0	6cc (84)	5cc (82)	B
15	8		-78	6o (69)	5o (79)	A	30			-78	6dd (82)	5dd (92)	A

^aTemperature (°C) when *N*-trimethylsilylaldimine was added to organometallic reagents. ^bIsolated yields (%) in parenthesis. ^cWork-up procedure A, B, or C.



Scheme 4

low temperature to provide amines **6** in good to high yields (Scheme 3).⁹ Next, two reaction conditions were evaluated to effect cyclization. Amines **6** were treated with 1,1'-thiocarbonyldiimidazole in CH_2Cl_2 to obtain the cyclic thioureas **5**. Alternatively, exposure of **6** to CS_2 and Et_3N in refluxing MeOH ¹⁰ led to the same products **5** in good to high yields. This method was superior to the former one with respect to yield and work-up. In most cases, the products **5** were precipitated out as the reaction proceeded. Overall, this two-step procedure enables us to rapidly access to various 1-substituted-imidazo[1.5-*a*]pyridine-3(2*H*)-thione derivatives.

As summarized in Table 1, we were able to incorporate aryl (**5a-5j**), benzyl (**5k-5o**), alkyl (**5p-5u**), heterocyclic (**5v-5cc**) groups at C1 of thioureas **5**, respectively. 2-Quinolinecarboxaldehyde (**12**) (entry 30) was also successfully utilized as aldehyde partner.

By following the route **B**, we also synthesized several derivatives containing one methyl group on the pyridine ring (1, 2, 3, and 4 position of **15**) although yields were poor (not optimized) (Scheme 4).¹¹

In conclusion, we have demonstrated a novel, two step approach to 1-substituted-imidazo[1.5-*a*]pyridine-3(2*H*)-thione derivatives¹² starting from aldehydes, employing the nucleophilic addition of organometallic compounds to aldimines prepared *in situ*. This process should be useful for the synthesis of structurally related thioureas given a number of readily available organometallic reagents. Biological evaluation of these new compounds are currently underway and will be reported in due course.

Typical Experimental Procedure

To a solution of 2-pyridinecarboxaldehyde (**8**) in THF was slowly added LHMDS solution (1.0 M in THF, 1.2 equiv) at 0 °C. After 20 min, this solution was transferred to a solution of organometallic reagents (purchased or freshly prepared by appropriate methods, 1.8-2.0 equiv) in THF at either 0 or -78 °C depending on the organometallic species. After the reaction was complete, the reaction mixture was quenched with H_2O . The mixture was diluted with ethyl acetate and washed with water and brine. The water layer was extracted with ethyl acetate one more. The combined organic layer was dried over MgSO_4 , filtered, and evaporated *in vacuo*.¹³ For characterization purposes, the resulting residue was further purified by column chromatography (hexane:ethyl acetate = 1:1 to ethyl acetate only to methylene chloride: methanol = 10:1) to give amines **6**.

Amines **6** were dissolved in MeOH , and CS_2 (7.2 equiv) and Et_3N (2.0 equiv) were added at room temperature. The reaction mixture was heated to reflux overnight. After being cooled to room temperature, the mixture was concentrated under reduced pressure. The following work-up procedures were chosen depending on the product solubility. **Work-up A:** The residue was diluted with methylene chloride and washed with water. The water layer was extracted with methylene chloride one more. The combined organic layer was dried with MgSO_4 , filtered, and evaporated *in vacuo*. The crude residue was suspended in small amount of ethyl acetate and filtered. Top solid was washed with small amount of ethyl acetate two or three times to afford cyclic thiourea **5**. **Work-up B:** In case of the product **5** slightly soluble in methylene chloride, the reaction mixture was concentrated *in vacuo*. The resulting residue was suspended in ethyl acetate and water. This mixture was then filtered and washed with water and ethyl acetate, successively. Even in the case where product was isolated by filtration, the filtrate was further purified by silica gel flash column chromatography for higher yields. **Work-up C:** In case of products very soluble in ethyl acetate and/or methylene chloride, the crude residue after aqueous work-up was purified by silica gel flash column chromatography (hexane:ethyl acetate:methylene chloride = 5:1:2 to 3:1:2).

Compound 5c: 300 MHz ^1H NMR ($\text{DMSO-}d_6$) δ 13.7 (1H, br s), 8.11 (1H, dt, $J = 7.4, 1.0$ Hz), 7.62 (2H, d, $J = 8.9$ Hz), 7.62-7.56 (1H, m), 7.03 (2H, d, $J = 8.9$ Hz), 6.82 (1H, ddd, $J = 9.4, 6.3, 1.0$ Hz), 6.67 (1H, ddd, $J = 7.3, 6.4, 1.0$ Hz), 3.79 (3H, s); 125 MHz ^{13}C NMR ($\text{DMSO-}d_6$) δ 158.7, 152.1, 127.4, 124.1, 122.9, 122.3, 120.9, 118.1, 117.4, 114.7, 113.2, 55.3; MS (EI) m/z [$\text{M}]^+$ for $\text{C}_{14}\text{H}_{12}\text{N}_2\text{OS}$: calcd 256.07, found 256, 241, 224, 182, 136. **Compound 5d:** 200 MHz ^1H NMR ($\text{DMSO-}d_6$) δ 13.8 (1H, br s), 8.17 (1H, dd, $J = 7.4, 1.2$ Hz), 7.85-7.60 (3H, m), 7.32 (2H, t, $J = 9.0$ Hz), 6.91 (1H, dd, $J = 6.4, 5.2$ Hz), 6.72 (1H, t, $J = 7.2$ Hz); 125 MHz ^{13}C NMR ($\text{DMSO-}d_6$) δ 162.2, 160.3, 128.1, 128.0, 125.0, 124.9, 124.3, 123.7, 123.1, 117.9, 116.3, 116.2, 116.1, 113.3; MS (EI) m/z [$\text{M}]^+$ for $\text{C}_{13}\text{H}_9\text{FN}_2\text{S}$: calcd 244.05, found 244, 212, 185, 157, 122. **Compound 5e:** 200 MHz ^1H NMR ($\text{DMSO-}d_6$) δ 13.9 (1H, br s), 8.19 (1H, dd, $J = 7.2, 0.8$ Hz), 7.85-7.60 (3H, m), 7.51 (2H, d, $J = 9.0$ Hz), 6.94 (1H, dd, $J = 9.4, 6.6$ Hz), 6.74 (1H, dd, $J = 7.2, 6.4$ Hz); 125 MHz ^{13}C NMR ($\text{DMSO-}d_6$) δ 153.1, 131.6, 129.1, 127.4, 127.2, 124.4, 124.2, 123.6, 117.9, 115.9, 113.4; MS (EI) m/z [$\text{M}]^+$ for $\text{C}_{13}\text{H}_9\text{ClN}_2\text{S}$: calcd 260.02, found 260, 225, 201, 192, 166. **Compound 5k:** 200 MHz ^1H NMR ($\text{DMSO-}d_6$) δ 13.4 (1H,

br s), 7.96 (1H, dt, $J = 7.2, 1.2$ Hz), 7.42 (1H, dt, $J = 9.4, 1.6$ Hz), 7.40-7.08 (5H, m), 6.68 (1H, ddd, $J = 9.4, 6.6, 1.4$ Hz), 6.56 (1H, ddd, $J = 7.6, 6.4, 1.6$ Hz), 4.10 (2H, s); 125 MHz ^{13}C NMR (DMSO- d_6) δ 140.4, 132.6, 129.3, 128.5, 128.3, 125.9, 125.2, 122.5, 119.3, 117.5, 113.1, 32.9; MS (EI) m/z $[\text{M}]^+$ for $\text{C}_{14}\text{H}_{12}\text{N}_2\text{S}$: calcd 240.07, found 240, 221, 205, 180, 152. **Compound 5n**: 200 MHz ^1H NMR (CDCl_3) δ 12.0 (1H, br s), 8.11 (1H, d, $J = 7.4$ Hz), 7.13 (2H, d, $J = 8.6$ Hz), 7.00 (1H, d, $J = 9.4$ Hz), 6.84 (2H, d, $J = 8.6$ Hz), 6.61 (1H, dd, $J = 9.4, 5.6$ Hz), 6.49 (1H, t, $J = 6.4$ Hz), 4.08 (2H, s), 3.78 (3H, s); 125 MHz ^{13}C NMR (DMSO- d_6) δ 158.0, 150.9, 130.7, 129.4, 123.8, 123.5, 120.1, 117.9, 117.7, 114.0, 112.6, 55.1, 28.4; MS (EI) m/z $[\text{M}]^+$ for $\text{C}_{15}\text{H}_{14}\text{N}_2\text{OS}$: calcd 270.08, found 270, 237, 210, 167, 121. **Compound 5r**: 200 MHz ^1H NMR (CDCl_3) δ 8.13 (1H, d, $J = 7.2$ Hz), 7.18 (1H, dd, $J = 9.4, 1.2$ Hz), 6.60 (1H, t, $J = 6.4$ Hz), 6.49 (1H, t, $J = 6.4$ Hz), 3.27 (1H, septet, $J = 7.4$ Hz), 1.40 (6H, d, $J = 7.4$ Hz); 125 MHz ^{13}C NMR (DMSO- d_6) δ 150.8, 124.2, 123.4, 122.2, 119.5, 117.9, 112.5, 24.1, 22.2; MS (EI) m/z $[\text{M}]^+$ for $\text{C}_{10}\text{H}_{12}\text{N}_2\text{S}$: calcd 192.07, found 191.9 (97), 176.9 (100), 131.8 (14), 116.9 (58). **Compound 5z**: 300 MHz ^1H NMR (DMSO- d_6) δ 13.8 (1H, br s), 8.06 (1H, d, $J = 7.4$ Hz), 7.65 (1H, dt, $J = 9.4, 1.1$ Hz), 6.86 (1H, dd, $J = 9.4, 6.0$ Hz), 6.76 (1H, d, $J = 3.3$ Hz), 6.68 (1H, t, $J = 7.2$ Hz), 6.22 (1H, dd, $J = 3.3, 1.0$ Hz), 2.35 (3H, s); 125 MHz ^{13}C NMR (DMSO- d_6) δ 152.6, 151.6, 142.6, 124.0, 122.6, 122.5, 118.7, 113.5, 109.9, 107.8, 106.8, 13.4; MS (EI) m/z $[\text{M}]^+$ for $\text{C}_{12}\text{H}_{10}\text{N}_2\text{OS}$: calcd 230.05, found 230.0 (100), 186.9 (68), 171.8 (14), 127.9 (25). **Compound 5dd**: 200 MHz ^1H NMR (DMSO- d_6) δ 13.6 (1H, br s), 10.9 (1H, d, $J = 8.6$ Hz), 7.66 (1H, dd, $J = 7.4, 2.0$ Hz), 7.58 (2H, d, $J = 8.2$ Hz), 7.57-7.34 (3H, m), 7.32 (2H, d, $J = 8.0$ Hz), 7.13 (1H, d, $J = 9.4$ Hz), 2.37 (3H, s); 125 MHz ^{13}C NMR (DMSO- d_6) δ 157.0, 137.9, 134.9, 129.7, 127.8, 127.1, 127.0, 126.1, 125.7, 124.7, 124.0, 123.0, 120.4, 117.2, 116.2; MS (EI) m/z $[\text{M}]^+$ for $\text{C}_{18}\text{H}_{14}\text{N}_2\text{S}$: calcd 290.09, found 290.1 (100), 230.1 (35), 217.1 (13), 144.9 (19).


Acknowledgements. We thank the Center for Biological Modulators and Korea Research Institute of Chemical Technology for generous financial support.

References and Notes

1. Glover, E. E.; Vaughan, K. D.; Bishop, D. C. *J. Chem. Soc.*,

Perkin Trans. 1 **1973**, 2595.

2. Recently, Movassaghi and Schmidt converted **i** to **ii** to measure the enantiomeric excess of the chiral imidazopyridinium derivatives they prepared. - *Tetrahedron Lett.* **2007**, *48*, 101.



3. Winthrop, S. O.; Gavin, G. *J. Org. Chem.* **1959**, *24*, 1936.
4. For the synthesis of phenyl 2-pyridyl ketone, see: (a) Niemers, E.; Hiltmann, R. *Synthesis* **1976**, 593. (b) Weiberth, F. J.; Hall, S. S. *J. Org. Chem.* **1987**, *52*, 3901. (c) Negi, S.; Matsukura, M.; Mizuno, M.; Miyake, K.; Minami, N. *Synthesis* **1996**, 991. (d) Cuperly, D.; Gros, P.; Fort, Y. *J. Org. Chem.* **2002**, *67*, 238. (e) Popova, I. S.; Formanovsky, A. A.; Mikhura, I. V. *Russ. Chem. Bull., Int. Ed.* **2002**, *51*, 540. (f) Maerten, E.; Hassouna, F.; Couve-Bonnaire, S.; Mortreux, A.; Carpentier, J.-F.; Castanet, Y. *Synlett* **2003**, 1874. (g) Wittenberg, R.; Srogl, J.; Egi, M.; Liebeskind, L. S. *Org. Lett.* **2003**, *5*, 3033. (h) Yin, Z.; Zhang, Z.; Kadow, J. F.; Meanwell, N. A.; Wang, T. *J. Org. Chem.* **2004**, *69*, 1364. (i) Hosseini Savari, M.; Sharghi, H. *Synthesis* **2004**, 2165.
5. For recent reviews on nucleophilic addition to imines, see: (a) Vilaivan, T.; Bhanthumnavin, W.; Sritana-Anant, Y. *Curr. Org. Chem.* **2005**, *9*, 1315. (b) Savoia, D. In *Topics in Organometallic Chemistry*; Lemaire, M.; Mangeney, P., Eds.; Springer: Berlin Heidelberg, 2005; Vol.15, pp 1-58. (c) Petrimi, M.; Torregiani, E. *Synthesis* **2007**, 159.
6. (a) Hart, D. J.; Kanai, K.-i. *J. Org. Chem.* **1982**, *47*, 1555. (b) Hart, D. J.; Kanai, K.-i.; Thomas, D. G.; Yang, T.-K. *J. Org. Chem.* **1983**, *48*, 289. (c) Hart, D. J.; Hong, W.-P.; Hsu, L.-Y. *J. Org. Chem.* **1987**, *52*, 4665.
7. For nucleophilic addition of CN to *N*-TMS aldimines, see: Chu, G.-H.; Gu, M.; Gerard, B.; Dolle, R. E. *Synth. Comm.* **2004**, *34*, 4583. - Two substrates (2- and 3-pyridinealdehydes) examined in this reaction furnished the desired α -aminonitriles in low yield.
8. For example, competitive enolization of the aldehydes and/or isomerization of the imines to enamines might occur in case of enolizable aldehydes.
9. Since the stereochemistry at C1 is inconsequential in our case, we did not attempt to use any chiral ligands for asymmetric induction.
10. Bristol, J. A.; Lovey, R. G. *U.S. Patent 4,419,516*, 1982.
11. Presumably, halogen-metal exchange of methyl-substituted 2-bromopyridines competes with deprotonation of other position.
12. All new compounds exhibited satisfactory spectral and analytical data.
13. Since the crude residue after aqueous work-up was pure enough for the subsequent reaction with CS_2 and Et_3N in refluxing MeOH in most cases, no column chromatography was undertaken, which provided comparable overall yields.